CAPOX
8 clinical trials
3 products
101 abstracts
8 indications
Indication
Colorectal CancerIndication
Colon CancerIndication
Rectal NeoplasmsIndication
Rectal CancerIndication
Stomach CancerIndication
Peritoneal MetastasesIndication
Locally Advanced Rectal CancerIndication
Narcolepsy Type 1Abstract
First-line osemitamab (TST001) plus nivolumab and capox for advanced g/GEJ cancer (TranStar102): Results of cohort G from a phase I/IIa study.Org: Fujian Cancer Hospital, Fuzhou, China, Medical Oncology Department of Gastrointestinal Cancer, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, China, Department of Gastrointestinal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Central Hospital Affiliated to Shandong First Medical University; Jinan Central Hospital, Shandong University, Jinan, China, Affiliated Hospital Zhejiang University, Hangzhou, China,
Abstract
Total neoadjuvant therapy with split-course hypofraction radiotherapy combined with CAPOX and envafolimab followed by local excision for locally advanced very low rectal cancer (TRACE-LE): An open-label, single-arm, multicenter, phase II trial.Org: Department of Colorectal Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China, Union Hospital Medical College, Huazhong University of Science and Technology, Wuhan, China, Longyan Affiliated Hospital, Fujian Medical University, Longyan, China, Fujian Provincial Cancer Hospital, Fuzhou, China, Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, People’s Republic of China, Fuzhou, China, Department of Colorectal Surgery, Fujian Medical University Union Hospital, Fuzhou, China,
Abstract
Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO.Org: Oncology Unit Santa Maria delle Croci Hospital, Cardinale G Panico, Azienda Toscana Nord Ovest, University Hospital of Pisa,
Abstract
NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).Org: NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, NSABP Foundation, Inc., UPMC Hillman Cancer Center, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC,
Abstract
Safety and efficacy results from the phase I/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18.2+/HER2- locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.Org: FutureGen Biopharmaceutical (Beijing) Co, Beijing, Beijing, China, Futuregen Biopharmaceutical (Beijing) Co., Ltd, Beijing, China, FutureGen Biopharmaceutical (Beijing) Co., Beijing, China,
Abstract
The NEO-RT trial: A phase 3 randomized trial of neoadjuvant chemotherapy, excision and observation versus chemoradiotherapy for early rectal cancer, CCTG CO.32.Org: Roswell Park Comprehensive Cancer Institute,
Abstract
Impact of DNA damage repair alterations on real-world response to therapy in metastatic colorectal cancer.Org: Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
A multicenter single-arm phase II study examining the efficacy of TNT for locally advanced rectal cancer: ENSEMBLE-2.Org: Akita Red Cross Hospital, Akita, Japan, Department of Digestive and General Surgery, Faculty of Medicine, University of the Ryukyus, Nakagami-Gun Nishihara-Cho, Japan, Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan, Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan, Department of Gastroenterological Surgery and Pediatric Surgery, Gifu University Graduate School of Medicine, Nishinomiya, Japan,
Abstract
Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, phase II study.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Union Hospital Medical College,
Clinical trial
A Phase III Randomized Trial Investigating the Duration of Adjuvant Therapy(3 Versus 6 Months) With the Modified FOLFOX 6 or XELOX Regimens for Patients With Stage III Colon CancerStatus: Active (not recruiting), Estimated PCD: 2020-01-01
Clinical trial
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS TrialStatus: Active (not recruiting), Estimated PCD: 2024-07-15
Clinical trial
MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy (SCPRT) Followed by Consolidation Chemotherapy Versus Long Course Chemoradiation for Unresectable Rectal CancerStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)Status: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric OriginStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Multicenter Randomized Phase III Study of Short-term Radiotherapy Plus CAPOX and Short-term Radiotherapy Plus CAPOXIRI as Preoperative Treatment for Locally Advanced Rectal CancerStatus: Recruiting, Estimated PCD: 2029-12-31
Clinical trial
Total Neoadjuvant Therapy With Split-course Hypofraction Radiotherapy Combined With CAPOX and Envafolimab Followed by Local Excision for Locally Advanced Very Low Rectal Cancer: an Open-label, Single-arm, Multi-center, Phase II TrialStatus: Not yet recruiting, Estimated PCD: 2027-12-31
Abstract
Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.Org: Westwood, Kansas City, Department of Biostatistics & Data Science, Central Care Cancer Ctr, The University of Kansas Cancer Center,
Abstract
Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.Org: Danish Colorectal Cancer Center South, Vejle Hospital, Gastro Unit, Department of Oncology, National Taiwan University Hospital, Department of Oncology and Palliative Units,
Abstract
Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).Org: Narayana Multispeciality Hospital, Tata Memorial Hospital, Homi Bhabha cancer hospital and research centre, Regency Hospital, National Cancer Insitute,
Abstract
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.Org: Medical Oncology Department, Rene Gauducheau Cancer Center, Institut De Cancerologie D'Ouest Centre Paul Papin, Hôpital Saint Grégoire, Faculté de Médecine Paris-Sud,
Abstract
A randomized study of consolidation chemoradiation (CTRT) vs observation after first-line chemotherapy (CT) in advanced gall bladder cancers (GBC): RACE-GB Study.Org: SGPGI, Sanjay Gandhi Postgraduate Institute of Medical Sciences,
Abstract
ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.Org: Shizuoka Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Beijing Cancer Hospital, Department of Oncology, National Taiwan University Hospital,
Abstract
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).Org: Memorial Sloan Kettering Cancer Center, Alliance Statistics and Data Center, Mayo Clinic, Department of Radiology, Department of Colorectal Oncology,
Abstract
Cyclin E cytoplasmatic isoform to predict outcome and benefit to capecitabine treatment in patients with HR+/HER2- metastatic breast cancer from the GEICAM/2013-02 PEARL study.Org: Instituto Valenciano de Oncología, Institut Català d'Oncologia (ICO) & IDIBELL, Medical University Vienna, Central European Cooperative Oncology Group, Medical Oncology Department,
Abstract
PACE: A phase III trial of CAPOX versus anti-PD-1 inhibitor as adjuvant therapy for patients with dMMR/MSI-H stage III colon cancer.Org: Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China, Biotherapy Center,
Abstract
Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW).Org: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China, Astellas Pharma Global Development, Inc., Northbrook, IL, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Weill Cornell Medical College, New York, NY,
Abstract
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial.Org: Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, Department of Breast Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Breast Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Liaoning, China,
Abstract
Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases.Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China, Department II of breast, Linyi Cancer Hospital,
Abstract
Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine.Org: All India Institute of Medical Sciences, Dr. Brairch, Abbisko Therapeutics, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, All India Institute of Medical Science (AIIMS),
Abstract
A multicenter, open-label, randomized phase II study evaluating adjuvant gemcitabine plus cisplatin (GC) and capecitabine with concurrent capecitabine radiotherapy (CAPE-RT) in patients with operated gallbladder adenocarcinoma (GBC): The GECCOR-GB trial.Org: Tata Memorial Hospital (HBNI), HBNI, HBNI University, Homi Bhabha cancer hospital and research centre, Homi Bhabha Cancer Hospital &Research Centre,
Abstract
Negative estrogen receptor expression assessed by 18F-FES PET in metastatic breast cancer with ER-positive primary tumor.Org: Fudan University Shanghai Cancer Center, Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital,
Abstract
Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer.Org: Duke University Cancer Institute, Seagen, Inc., Genesis Research, Winship Cancer Institute, Emory University School of Medicine,
Abstract
Disease outcomes by race in patients with high-risk triple negative breast cancer with residual disease after neoadjuvant chemotherapy: A post-hoc analysis of the EA1131 randomized clinical trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Dana-Farber Cancer Institute, MD Anderson Cancer Center, Division of Breast Surgery,
Abstract
Pilot study of a micro-organosphere drug screen platform to lead care in advanced breast cancer (MODEL-ABC).Org: Xilis, Duke University Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Xilis, Inc., Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Differential benefit of capecitabine-based chemotherapy among TNBC subtypes in the context of the CBCSG010 study.Org: Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Department of Breast Surgery, Kyorin University School of Medicine/Saitama Medical Center, Tokyo, Japan, Key Laboratory of Breast Cancer in Shanghai, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Cancer of unknown primary with gastrointestinal profiles: A distinct CUP subset.Org: Baylor College of Medicine, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, MD Anderson Cancer Center Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Real-world experience of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test to guide fluoropyrimidine (FP) dosing at a multisite cancer hospital.Org: Levine Cancer Institute, Atrium Health Carolinas Medical Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
Mismatch Repair system protein deficiency as a factor of resistance to chemo-radiotherapy treatment in patients with locally advanced rectal adenocarcinoma and its influence on disease-free survival.Org: Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy, Clinica Oncologica - Dipartimento Scienze Cliniche e Molecolari - Università Politecnica delle Marche & Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of General Surgery, University of Cagliari, Cagliari, Italy,
Abstract
A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).Org: Mass General Cancer Center, Mayo Clinic, University of California Irvine, Duke University Medical Center, The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA,
Abstract
Adjuvant nab-paclitaxel plus S-1 versus capecitabine plus oxaliplatin for patients with stage III gastric adenocarcinoma after D2 dissection: A multicenter, open-label, randomized phase 3 study.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, University of Chinese Academy of Sciences Cancer Hospital, Hepato-Pancreato-Biliary & Gastric Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences,
Abstract
A prospective evaluation of pelvic radiation vs. no radiation among patients with young-onset rectal cancer: Impact on patient-reported outcomes.Org: University of Texas MD Anderson Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Department of Gastrointestinal Radiation Oncology, University of Texas MD Anderson Cancer Center, Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial).Org: Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, University of Milano, European Institute of Oncology, Division of Early Drug Development, European Institute of Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study.Org: Innovent Biologics, Inc.,
Abstract
Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.Org: University of Washington/Fred Hutchinson Cancer Research Center, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Sarah Cannon Research Institute at HealthONE, University of Michigan Rogel Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery.Org: Dana-Farber Cancer Institute, University of Pennsylvania, The Cancer Institute Hospital of JFCR, Tokyo, Japan, University of California Comprehensive Cancer Center, University of North Carolina at Chapel Hill,
Abstract
Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): First results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer group.Org: Grow School for Oncology and Reproduction, European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, European Institute of Oncology - IRCCS, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Robert Debré University Hospital,
Abstract
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.Org: Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL, USA, Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, MA, USA, Massachusetts General Hospital, Columbia University Irving Medical Center, New York, NY, USA, University of Virginia, Charlottesville, VA, USA,
Abstract
HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.Org: Sarah Cannon Research Institute at Tennessee Oncology, PLLC, Hospital General Universitario Gregorio Marañón, Mayo Clinic, European Institute of Oncology, Yonsei Cancer Center, Yonsei University Health System,
Abstract
KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.Org: Yonsei Cancer Center, Yonsei University Health System, Maria Sklodowska-Curie National Research Institute of Oncology, James Lind Cancer Research Center, Temuco, Chile, Harbin Medical University Cancer Hospital, Asan Medical Center,
Abstract
MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, OneOncology, Inc., New York Cancer and Blood Specialists,
Abstract
A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity.Org: Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, Cardiff University, School of Medicine, Cardiff, United Kingdom, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, United Kingdom,
Abstract
Ultra-sensitive, tumor-informed ctDNA profiling in patients with gastroesophageal cancer and treated with pembrolizumab and longitudinal ctDNA kinetics.Org: Duke University Medical Center, Personalis, Inc., University of North Carolina at Chapel Hill, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.Org: American University of Beirut Medical Center, National Cancer Centre of Singapore, Acıbadem Research Institute of Senology, Medical Oncology, Seoul National University Hospital, Independent Patient Advocate,
Abstract
Updated results and biomarker analyses from the phase 2 trial (BBCAPX study) of sintilimab plus bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China,
Abstract
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.Org: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Department of Medical Oncology, Kochi Medical School, Nankoku-City, Japan, National Cancer Center Hospital East, Japan, Kashiwa-Shi, Japan, Department of Gastroenterological Oncology, Saitama Medical University International Medical Center, Saitama, Japan, Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan,
Abstract
A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.Org: University of Texas Southwestern Medical Center, Memorial Sloan Kettering Cancer Center, CLION-CAM Group, Cedars-Sinai Medical Center, Cedars-Sinai Cancer,
Abstract
Investigating alterations in cancer driver genes and other potentially targetable mutations in patients with intrahepatic cholangiocarcinoma (iCCA) treated on the randomised phase III multicentre BILCAP clinical trial.Org: UCL-University College London (United Kingdom ), University of Edinburgh Cancer Research UK Centre, Institute of Cancer & Genomic Sciences, University of Birmingham, University of Southampton NHS Foundation Trust, Bill Lyons Informatics Centre, London,
Abstract
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Alliance Statistics and Data Center, Mayo Clinic, University of North Carolina at Chapel Hill,
Abstract
Neoadjuvant short-course radiotherapy followed by chemotherapy plus camrelizumab versus long-course chemoradiotherapy followed by chemotherapy for patients with locally advanced rectal cancer: A randomized, multicenter, open-label phase 3 trial (Union).Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, Hubei, China,
Abstract
The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Walter & Eliza Hall Institute of Medical Research and Western Health, Melbourne, Australia, Alfred Hospital Melbourne, Monash Cancer Centre, Royal North Shore Hospital, Sydney, Australia,
Abstract
AdvanTIG-105: A phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC).Org: BeiGene (USA) Co., Ltd., BeiGene (Shanghai) Co., Ltd., Sarah Cannon Research Institute/Tennessee Oncology, Monash Heath and Faculty of Medicine, Nursing and Health Sciences, Mayo Clinic,
Abstract
The CIRCULATE Spain study: Circulating tumor DNA based decision for adjuvant treatment in localized colon cancer.Org: INCLIVA Biomedical Research Institute, University of Valencia, Instituto Carlos III, CIBERONC, Biostatistics Unit,
Abstract
BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC).Org: MD Anderson Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Asan Medical Center, Hammersmith Hospital, Imperial College, London, United Kingdom, Department of Gastroenterology/Digestive Oncology,
Abstract
Utility of circulating tumor DNA (ctDNA) as a predictive biomarker for disease monitoring in patients (pts) with cholangiocarcinoma (CCA) before and during adjuvant chemotherapy (ACT): Sub-analysis of the randomized phase 2 STAMP trial.Org: Natera, Inc., Asan Medical Center, University of Ulsan College of Medicine, Digestive Disease Research Center,
Abstract
STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.Org: Mass General Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Arcus Biosciences, Gilead Sciences, Inc., Memorial Sloan Kettering Cancer Center,
Abstract
ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer.Org: Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Uniklinik Göttingen, Universitätsklinikum Ulm,
Abstract
Comparison of adjuvant capecitabine plus oxaliplatin (CAPOX) versus S-1 in patients with gastric cancer after gastrectomy based on the registry data base on the National Health Insurance Service (NHIS) database in Korea.Org: Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul National University Hospital, South Korea, Department of Data Sciences,
Abstract
Impact of use of CDK4/6i and neratinib among patients with HER2 +ve MBC: Results from a real world dataset.Org: Mediclinic City Hospital, TriNetX Europe,
Abstract
Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): A single-center, real-world study.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, First Affiliated Hospital of Xi’an Jiaotong University,
Abstract
Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial.Org: Rutgers Cancer Institue of New Jersey, Winship Cancer Institute, Emory University School of Medicine, Division of Surgical Oncology, Department of Surgery, The Ohio State University, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Emory University, Atlanta, GA, USA,
Abstract
Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomized clinical trial.Org: Klinikum Grosshadern University Hospital Med Center, München, Germany,
Abstract
Anal carcinoma: A retrospective analysis in a Mexican cohort.Org: Centro Universitario contra el Cáncer, Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”,
Abstract
National trends in neoadjuvant chemotherapy utilization for cT1-2 N0 triple negative breast cancer: Did the CREATE-X trial impact treatment patterns?Org: Medical College of Wisconsin, University of Wisconsin-Milwaukee, University of Texas MD Anderson Cancer Center,
Abstract
Making sense of the dollars: Evaluation of financial toxicity in patients of breast medicine receiving oral chemotherapy at Roswell Park.Org: Roswell Park Comprehensive Cancer Center, The D'Youville University School of Pharmacy,
Abstract
Characterization of patients with recurrent breast cancer submitted to neoadjuvant therapy in a Brazilian cancer center.Org: A.C. Camargo Cancer Center, Hospital ACCamargo, A.C. Camargo Hospital,
Abstract
Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with heavily pretreated HER2 positive advanced breast cancer: A retrospective single institution study.Org: University of California, Irvine, Irvine, CA, UC Irvine Health, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Nepal Medical College and Teaching Hospital, Kathmandu Medical College and Teaching Hospital,
Abstract
Clinical and molecular characterization of a cohort with breast cancer brain metastases.Org: Oregon Health & Science University, Portland, OR, Internal Medicine Residency,
Abstract
Safety and efficacy study of oral metronomic capecitabine in combination with pyrotinib for HER2‑positive metastatic breast cancer: A phase II trial.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.Org: University of Chicago Medicine, The University of Chicago Medicine Center for Advanced Care at Orland Park, University of Chicago, UT Southwestern Medical Center, Center for Data Intensive Science at the University of Chicago,
Abstract
Survival outcomes with observation or adjuvant therapy in elderly patients with biliary tract cancer.Org: Emory University School of Medicine, Winship Cancer Institute, Emory University School of Medicine, Winship Cancer Center of Emory University, Winship Cancer Institute of Emory University, Winship Cancer Institute, Division of Surgical Oncology, Department of Surgery, Emory University,
Abstract
Radiotherapy combined with pyrotinib plus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and brain metastases: A single-arm, exploratory trial.Org: Department of Radiotherapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China, Department of Breast Surgery, Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China, Department of Breast Medicine, Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China,
Abstract
Preliminary analysis of pyrotinib and dalpiciclib-based therapy in HER2-positive advanced breast cancer (ABC).Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US).Org: Dana-Farber Cancer Institute, University Hospitals Leuven, Leuven, Belgium, Stanford University School of Medicine, Gilead Sciences Europe Ltd., Gilead Sciences Inc.,
Abstract
A pilot study of the combination of entinostat with capecitabine in high-risk breast cancer after neoadjuvant therapy.Org: University of Virginia Health System, University of Virginia, Charlottesville, VA, USA, James P. Wilmot Cancer Center/URMC - Pluta, University of Rochester Medical Center Department of Medical Oncology, VCU Department of Biostatistics,
Abstract
Hypertriglyceridemia associated with the use of capecitabine in a Mexican cohort.Org: Hospital Ángeles Lindavista, Arké SMO,
Abstract
Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with pembrolizumab in early-stage, triple-negative breast cancer.Org: Duke University Hospital, Duke Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Health System,
Abstract
Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001).Org: Ruijin Hospital, Shanghai Jiaotong University School, Shanghai, China, Shanghai Jiao Tong University School of Medicine, Jiading Central Hospital, Affiliated Hospital of Jiangnan University (Wuxi Fourth People's Hospital), Wuxi Branch of Ruijin Hospital,
Abstract
Association of treatment regimens with quality of life and overall survival in patients with metastatic colorectal cancer in Peru.Org: Oncosalud-AUNA, San Borja, Peru,
Abstract
The safety and efficacy of cadonilimab in combination with AK117 (anti-CD47 antibody) plus chemotherapy as first-line treatment for advanced gastric (G) or gastroesophageal junction (GEJ) cancer.Org: Akeso Biopharma, Inc., Zhongshan, China,
Abstract
Clinical outcomes of patients who underwent total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): A single center experience.Org: MUSC Health, Medical University of South Carolina Hollings Cancer Center,
Abstract
Implementation of 3 month therapy for stage III colon cancer in a large community practice.Org: JT Mather/Northwell Health, NY Cancer and Blood Specialists,
Abstract
Pathologic complete response (pCR) to neoadjuvant treatment (NAT) with carboplatin, nab-paclitaxel and anthracycline in early and locally advanced triple-negative breast cancer (TNBC).Org: Medical Oncology Department, University Hospital Virgen del Rocío, Sevilla, Spain, Medical Oncology Department, University Hospital Puerto Real, Cádiz, Spain, Medical Oncology Department, University Hospital Virgen Macarena, Sevilla, Spain, University Hospital Virgen del Rocío, Sevilla, Spain, Hospital Virgen del Rocio de Sevilla. GEICAM Spanish Breast Cancer Group, Seville, Spain,
Abstract
Efficacy and safety of camrelizumab and apatinib combined with neoadjuvant concurrent chemoradiation for MSS locally advanced rectal cancer.Org: Affiliated Hospital of Qingdao University, Qingdao University Affiliated Hospital,
Abstract
Characterization of drug and non-drug interactions in patients treated in medical oncology.Org: Faculty of Medicine, University of Tlemcen, Department of Medicine, Laboratoire Toxicomed, University of Tlemcen, Department of Medical Oncology, CHU Tlemcen,
Abstract
Capecitabine-oxaliplatin (CAPOX) prior to chemoradiotherapy (CRT) and surgery in magnetic resonance imaging (MRI)-defined poor-risk rectal carcinoma (PRRC): A single center experience.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Provincial de Castellon, Castellon, Spain, Hospital Provincial de Castellón,
Abstract
ADC vs HP dual-antibody for HER2-positive advanced breast cancer after failed to TKI.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China, Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China, Department of Breast Cancer, the Fifth Medical Center Affiliated to PLA General Hospital, Beijing, China,
Abstract
A single-institution analysis of a rare variant of pancreatic neoplasm-osteoclastic giant cell tumor.Org: University of Nebraska Medical Center, Omaha, NE,
Abstract
Treatment and outcomes of pancreatic cancer in Armenia: Hospital-based study.Org: Immune Oncology Research Institute, National Center of Oncology named after V.A. Fanarjyan, Hematology center after prof. Yeolyan, Mikaelyan Institute of Surgery, City University of Hong Kong,
Abstract
Adjuvant capecitabine in advanced nasopharyngeal carcinoma following concurrent chemoradiotherapy: A meta-analysis and systematic review.Org: Lung Center of the Philippines, University of the Philippines- Philippine General Hospital, Makati Medical Center, National Cancer Centre Singapore,
Abstract
Oxaliplatin based chemotherapy for advanced well-differentiated neuroendocrine tumors: A systematic review and meta-analysis.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Qilu Hospital of Shandong University, Jinan, China National Biotec Group,
Abstract
Canadian (CAN) real-world outcomes for relapsed/recurrent (R/R) metastatic triple-negative breast cancer (mTNBC) in the first-line or later (1L+) setting by early or late recurrence status.Org: Gilead Sciences Canada, University of Calgary, Gilead Sciences Europe Ltd.,
Abstract
Sex difference in tolerability of adjuvant oxaliplatin-based chemotherapy for colorectal cancer and changes in diagnostic components of sarcopenia: A prospective study.Org: Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan, Department of Surgical Oncology, The Univeristy of Tokyo, Tokyo, Japan, Department of Geriatric Medicine, The University of Tokyo, Tokyo, Japan,
Abstract
Efficacy of low dose sorafenib and capecitabine in the management of hepatocellular cancer.Org: Department of Radiotherapy and Oncology, University Hospital Center Osijek, MINAR Cancer Hospital, Multan Cancer Hospital,
Abstract
Total neoadjuvant therapy for locally advanced rectal cancer: A western Australian experience.Org: UWA Medical School, University of Western Australia & Linear Clinical Research, Department of Medical Oncology, Fiona Stanley Hospital, Colorectal Unit, Department of General Surgery, St. John of God Midland Hospital, Icon Cancer Centre, Midland,
Abstract
Tolerability of capecitabine in difference racial/ethnic groups.Org: Tufts Medical Center Hematology-Oncology Fellowship, Boston, MA, Tufts Medical Center/Tufts University, Brookline, MA,
Product
CAPOXAbstract
Oral capecitabine or tegafur/gimeracil/oteracil as induction and adjuvant/maintenance chemotherapy in the management of stage III-IVb nasopharyngeal carcinoma: A systematic-review and meta-analysis.Org: University of Santo Tomas, Manila, Philippines, Trinity College Dublin, Dublin, Ireland, Autonomous University of Baja California, Mexicali, Mexico, Einstein Medical Center, Philadelphia, PA, Bridgeport Hospital, Bridgeport, CT,
Product
SHR-1701、CAPOXClinical trial
A Randomized, Double-Blind, Single-Dose, 5-Period Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Subjects With Narcolepsy Type 1Status: Not yet recruiting, Estimated PCD: 2025-02-14